Concomitant Statin Use and Survival in Patients With Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis

相伴的 医学 他汀类 内科学 肿瘤科 危险系数 荟萃分析 癌症 人口 随机对照试验 重症监护医学 置信区间 环境卫生
作者
Yonghe Liao,Yuxuan Lin,Xinqi Ye,Jinhai Shen
出处
期刊:JCO oncology practice [Lippincott Williams & Wilkins]
被引量:2
标识
DOI:10.1200/op-24-00583
摘要

PURPOSE The prognostic significance of concomitant statin use in cancer treatment with immune checkpoint inhibitors (ICIs) remains a subject of ongoing investigation. This study aims to clarify the prognostic value of statin use in this patient population and to provide a robust, evidence-based foundation to guide therapeutic decisions. METHODS A systematic search strategy was used across a multitude of digital archives to exhaustively identify all relevant academic literature published up until June 20, 2024. Studies published in English that reported hazard ratios (HRs) for overall survival (OS) and/or progression-free survival (PFS), along with corresponding 95% CIs, were considered eligible for inclusion. Meta-analyses were conducted to calculate combined HRs with 95% CIs. RESULTS A total of 25 studies, involving 46,154 patients with cancer, were included in the meta-analysis. The pooled results indicated that concomitant statin use was linked to better OS (HR, 0.80 [95% CI, 0.71 to 0.92]) and PFS (HR, 0.80 [95% CI, 0.69 to 0.92]) in patients with cancer under ICI therapy. Sensitivity analyses further validated the consistency and robustness of the combined results. CONCLUSION On the basis of the available clinical evidence, the concomitant use of statin is linked to an improved prognosis in oncology patients on ICI-based therapy. These observations underscore the potential of statin as an important adjunctive therapy in the treatment paradigm for ICI-treated patients with cancer, thereby establishing their significance as a key consideration in clinical management strategies. Further randomized controlled trials are imperative to validate the effect of statin use within the realm of ICI therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gds2021完成签到 ,获得积分10
1秒前
你好呀嘻嘻完成签到 ,获得积分10
1秒前
梅特卡夫完成签到,获得积分10
3秒前
熊雅完成签到,获得积分10
4秒前
6秒前
睡到自然醒完成签到 ,获得积分10
7秒前
cis2014完成签到,获得积分10
9秒前
独特的大有完成签到 ,获得积分10
9秒前
量子星尘发布了新的文献求助10
10秒前
12秒前
xingyi完成签到,获得积分10
14秒前
15秒前
舒心的秋荷完成签到 ,获得积分10
18秒前
zz123发布了新的文献求助10
19秒前
liaomr完成签到 ,获得积分10
19秒前
粗犷的灵松完成签到,获得积分10
20秒前
吃小孩的妖怪完成签到 ,获得积分10
20秒前
ncuwzq完成签到,获得积分10
22秒前
yshj完成签到 ,获得积分10
23秒前
25秒前
净禅完成签到 ,获得积分10
27秒前
29秒前
迷人的寒风完成签到,获得积分10
30秒前
30秒前
water应助科研通管家采纳,获得10
31秒前
Lucas应助HHHAN采纳,获得10
33秒前
无情修杰完成签到 ,获得积分10
34秒前
小柒完成签到 ,获得积分10
36秒前
聪慧芷巧发布了新的文献求助10
37秒前
38秒前
42秒前
蓝意完成签到,获得积分0
43秒前
xiaohongmao完成签到,获得积分10
48秒前
51秒前
qweerrtt完成签到,获得积分10
58秒前
58秒前
与共发布了新的文献求助10
59秒前
carly完成签到 ,获得积分10
1分钟前
颢懿完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022